Age-Related Macular Degeneration: Symptoms, Types, Treatment and Prevention

Author: Dr Val Phua
Estimated reading time: 20 minutes

Age-related macular degeneration, commonly called AMD, is a condition that affects the macula—the central part of the retina responsible for detailed vision.

AMD can make it more difficult to:

Read
Recognise faces
See road signs
Drive
Use a phone or computer
Distinguish fine detail
See clearly in dim lighting

The condition usually affects people over the age of 55 and becomes more common with increasing age. AMD is a major cause of irreversible central visual impairment in older adults worldwide, and the number of affected people is expected to rise as populations age.

AMD does not usually cause complete darkness because peripheral vision is often preserved. However, advanced disease affecting both eyes can significantly reduce independence and interfere with reading, driving and many daily activities.

There are two main forms of advanced AMD:

Geographic atrophy, also called advanced dry AMD
Neovascular AMD, commonly called wet AMD

Dry AMD is more common and usually progresses gradually. Wet AMD is less common but may cause rapid and severe central visual loss if treatment is delayed.

The Quick Answer

What Is Age-Related Macular Degeneration?

AMD is a progressive condition affecting the macula.

The macula contains specialised retinal cells needed for:

Sharp central vision
Reading
Facial recognition
Colour perception
Fine visual detail

AMD develops through a combination of ageing, genetic susceptibility, environmental exposure and changes involving the retinal pigment epithelium, Bruch’s membrane, photoreceptors, choroid and complement immune system.

What Are the Main Symptoms?

Possible symptoms include:

Blurred central vision
Straight lines appearing bent or wavy
A dark, blurred or missing area in the centre of vision
Difficulty reading small print
Needing brighter light
Reduced contrast
Difficulty recognising faces
Slower adaptation when moving into a dark room
Colours appearing less vivid
Words or letters disappearing while reading

Early AMD frequently causes no symptoms and may be discovered during a routine dilated examination.

Is AMD an Emergency?

Dry AMD usually progresses gradually and is not generally an emergency.

However, arrange an urgent eye examination if you develop:

New distortion
Wavy lines
A sudden central blur
A new dark or blank central spot
A sudden reduction in vision
Objects appearing smaller in one eye
A sudden change detected on an Amsler grid

These symptoms may indicate conversion to wet AMD, which should be diagnosed and treated promptly.

Can AMD Be Cured?

There is currently no treatment that fully reverses AMD or restores retinal cells that have already been permanently damaged.

However:

Lifestyle changes may reduce modifiable risk.
AREDS2 supplements may reduce progression in selected patients.
Anti-VEGF injections can control wet AMD and preserve or improve vision in many patients.
Complement-inhibitor injections available in some countries can slow the enlargement of geographic atrophy.
Low-vision rehabilitation can help patients use their remaining vision more effectively.

Understanding the Macula

The Retina

The retina is a thin layer of light-sensitive tissue lining the inside of the back of the eye.

It converts light into electrical signals that travel through the optic nerve to the brain.

The Macula

The macula is the central portion of the retina.

It is responsible for detailed central vision used for:

Reading
Recognising faces
Looking directly at an object
Driving
Seeing fine detail
Colour discrimination

The very centre of the macula is called the fovea.

Central and Peripheral Vision

AMD mainly damages central vision.

A person with advanced AMD may be unable to see the face of someone directly in front of them but still detect:

The outline of the person
Objects to the side
Movement
Large shapes
The general layout of a room

Peripheral vision may therefore help with mobility even when detailed central vision is severely reduced.

What Happens in AMD?

Drusen Formation

Drusen are deposits that accumulate beneath the retinal pigment epithelium.

Small drusen can occur as part of normal ageing and do not always indicate significant disease.

Larger or more numerous drusen, particularly when accompanied by pigmentary changes, increase the risk of progression to advanced AMD. Drusen characteristics are used in clinical severity scales to estimate future risk.

Retinal Pigment Epithelium Dysfunction

The retinal pigment epithelium, or RPE, supports the overlying photoreceptors.

Its functions include:

Recycling visual pigments
Removing waste material
Maintaining the retinal environment
Supporting photoreceptor metabolism
Regulating movement between the retina and choroid

AMD can disrupt these functions and gradually damage photoreceptors.

Complement-System Activity

The complement system forms part of the body’s immune response.

Genetic and biological evidence suggests that abnormal complement regulation contributes to AMD development and progression in susceptible individuals. Several important AMD-associated genetic variants involve complement-related pathways.

Abnormal Blood-Vessel Growth

In wet AMD, abnormal blood vessels develop beneath or within the retina.

These vessels may:

Leak fluid
Bleed
Cause macular swelling
Lift the retinal pigment epithelium
Damage photoreceptors
Produce scar tissue

Vascular endothelial growth factor, or VEGF, is a major driver of this leakage and abnormal vessel growth.

The Stages of AMD

No AMD or Normal Ageing Changes

An eye may have:

No drusen
Only a few small drusen
No significant pigment changes
Normal central vision

Routine eye examinations remain important because risk increases with age.

Early AMD

Early AMD may involve small or medium-sized drusen without significant visual loss.

Most patients have:

No symptoms
Good reading vision
Good eye-chart acuity

AREDS2 supplements are not routinely recommended solely for early AMD because evidence of benefit applies mainly to patients at greater risk of advanced disease.

Intermediate AMD

Intermediate AMD may involve:

Large drusen
Numerous medium-sized drusen
Pigmentary abnormalities
Early areas of retinal or RPE degeneration

Symptoms may include:

Mild central blur
Reduced contrast
Needing brighter light
Slower dark adaptation
Difficulty with low-contrast print

Patients with intermediate AMD have a greater risk of progressing to geographic atrophy or wet AMD.

Late AMD

Late AMD includes:

Geographic atrophy
Neovascular or wet AMD

Either form can cause significant central visual impairment.

Some patients develop both types in the same eye.

Dry AMD

What Is Dry AMD?

Dry AMD, also called non-neovascular or non-exudative AMD, is the more common form.

It is characterised by changes such as:

Drusen
Pigment abnormalities
Retinal pigment epithelium dysfunction
Progressive photoreceptor loss
Areas of retinal thinning

Dry AMD often progresses slowly over years, although the rate varies substantially between patients.

Does Dry AMD Always Become Wet AMD?

No.

Dry AMD may:

Remain stable
Progress slowly
Develop geographic atrophy
Convert to wet AMD
Develop both atrophy and neovascular disease

The risk depends on the stage, drusen characteristics, pigment changes, genetics and the condition of the other eye.

Geographic Atrophy

What Is Geographic Atrophy?

Geographic atrophy is an advanced form of dry AMD.

It involves well-defined areas where:

Retinal pigment epithelial cells are lost
Photoreceptors degenerate
The underlying choroid becomes more visible
Visual sensitivity is permanently reduced

The atrophic areas may initially develop away from the fovea and gradually enlarge until central vision is affected.

What Does Geographic Atrophy Feel Like?

Patients may experience:

Missing letters or words
Blank areas while reading
Difficulty recognising faces
Reduced reading speed
Severe difficulty in dim lighting
Poor contrast
Central blind spots
Difficulty moving vision smoothly across a page

Visual acuity may remain deceptively reasonable while areas beside the central fixation point are already severely damaged.

Can Geographic Atrophy Be Treated?

In some countries, complement-inhibitor injections are available to slow geographic-atrophy enlargement.

Phase 3 trials of pegcetacoplan and avacincaptad pegol demonstrated slower lesion growth compared with sham treatment. These treatments do not restore lost retinal tissue or reliably improve ordinary letter-chart vision. They require repeated intravitreal injections and involve risks including inflammation, infection and development of neovascular AMD. Availability and regulatory approval vary by country.

Treatment decisions should consider:

Lesion location
Rate of progression
Vision in both eyes
Injection burden
Risk of complications
Local availability
Expected long-term benefit

Wet AMD

What Is Wet AMD?

Wet AMD is also called:

Neovascular AMD
Exudative AMD
Macular neovascularisation secondary to AMD

Abnormal blood vessels grow beneath or within the retina and may leak fluid or blood.

Without timely treatment, the leakage may cause:

Photoreceptor damage
Fibrosis
Disciform scarring
Permanent central visual loss

How Quickly Can Wet AMD Affect Vision?

Wet AMD may cause noticeable visual change over:

Days
Weeks
Occasionally a longer period

Some patients notice a sudden change after bleeding beneath the retina.

New distortion or a central dark area should not be monitored for several weeks before seeking care.

Can Wet AMD Occur Without Symptoms?

Yes.

Early or recurrent neovascular activity may be detected on OCT before the patient notices a major change.

Regular follow-up remains important even when vision seems stable.

Polypoidal Choroidal Vasculopathy

What Is Polypoidal Choroidal Vasculopathy?

Polypoidal choroidal vasculopathy, or PCV, is a form of macular neovascular disease characterised by abnormal branching choroidal vessels with aneurysmal or polyp-like dilations.

It may cause:

Recurrent fluid
Pigment epithelial detachments
Subretinal bleeding
Large macular haemorrhages
Scarring

PCV is particularly relevant in Asian populations and may require additional imaging or a modified treatment strategy.

How Is PCV Diagnosed?

Tests may include:

OCT
OCT angiography
Fluorescein angiography
Indocyanine-green angiography

Indocyanine-green angiography is particularly useful for visualising the choroidal vascular network and polypoidal lesions.

How Is PCV Treated?

Treatment may include:

Anti-VEGF injections
Photodynamic therapy
A combination of both

The treatment plan depends on:

Lesion characteristics
Bleeding
Fluid
Visual acuity
Previous treatment response
Availability of photodynamic therapy

Symptoms of AMD

No Symptoms

Early AMD may be detected only during a routine retinal examination.

Good visual acuity does not exclude early or intermediate disease.

Blurred Central Vision

Words, faces or objects in the centre may appear:

Blurred
Hazy
Less distinct
Difficult to focus on

Distortion

Straight lines may appear:

Bent
Wavy
Broken
Uneven

This is called metamorphopsia.

Examples include:

Door frames appearing curved
Bathroom tiles appearing irregular
Text lines bending
Window blinds looking distorted

New metamorphopsia is an important warning symptom for wet AMD or another macular condition.

A Central Dark or Blank Spot

A dark, grey or missing area may appear in the centre of vision.

This is called a central scotoma.

Reduced Contrast

Patients may struggle to distinguish:

A grey kerb from the road
Pale print from a white page
Facial features in dim light
Food on a similarly coloured plate
Steps with limited contrast

Difficulty in Dim Light

AMD can affect visual adaptation in low lighting.

Patients may need:

Brighter reading lamps
More time to adjust indoors
Additional light in corridors
Better contrast on stairs

Altered Size Perception

Objects may appear smaller in one eye than the other.

This is called micropsia and may occur when the macula is distorted or swollen.

Colour Changes

Colours may appear:

Duller
Less saturated
Different between the eyes

Does AMD Affect Both Eyes?

AMD commonly affects both eyes, but the severity may be unequal.

One eye may have:

Early changes

while the other has:

Intermediate AMD
Geographic atrophy
Wet AMD

Patients may not notice significant loss in one eye because the better eye compensates.

Testing one eye at a time can reveal changes that are hidden during binocular viewing.

Risk Factors

Increasing Age

Age is the strongest non-modifiable risk factor.

AMD becomes progressively more common after the age of 55, with the highest prevalence among older age groups.

Smoking

Smoking is the most important established modifiable risk factor.

Current smokers have a substantially greater risk of AMD than non-smokers, and smoking is associated with both geographic atrophy and neovascular AMD. Stopping smoking is one of the most important actions a patient can take to reduce future risk.

Family History and Genetics

AMD is influenced by many genetic variants.

A family history may increase risk, particularly when a parent or sibling has advanced AMD.

Important genetic pathways include:

Complement regulation
Lipid metabolism
Extracellular-matrix function
Inflammation
Angiogenesis

Routine commercial genetic testing is not usually required to diagnose AMD or determine whether a patient should take AREDS2 supplements.

Cardiovascular and Metabolic Health

Hypertension, cardiovascular disease and diabetes have been associated with AMD in observational research, although the strength of individual associations varies.

Managing these conditions remains important for general vascular and ocular health.

Diet

Observational studies suggest that dietary patterns rich in:

Leafy green vegetables
Colourful vegetables
Fruit
Fish
Nuts
Whole grains

may be associated with a lower risk of progression than diets dominated by highly processed foods and unhealthy fats.

Diet is not a cure and cannot replace ophthalmic treatment.

Obesity and Physical Inactivity

Maintaining an appropriate weight and regular physical activity supports cardiovascular health and may contribute to a healthier long-term risk profile.

Sunlight

Protecting the eyes from excessive ultraviolet exposure is sensible for general ocular health.

However, sunglasses should not be presented as a proven treatment for AMD or a substitute for smoking cessation, medical monitoring or AREDS2 supplementation when indicated.

How Is AMD Diagnosed?

Visual-Acuity Testing

Visual acuity measures the smallest high-contrast letters you can identify.

A patient may have early or intermediate AMD despite good visual acuity.

Dilated Retinal Examination

Dilating drops enlarge the pupil so the ophthalmologist can examine:

Drusen
Pigmentary changes
Retinal haemorrhage
Fluid
Fibrosis
Geographic atrophy
Other retinal disease

Fundus Photography

Retinal photographs document:

Drusen
Pigment changes
Haemorrhage
Atrophy
Disease progression

They are useful for comparing changes over time.

Optical Coherence Tomography

OCT produces detailed cross-sectional images of the retina.

It can detect:

Drusen
Retinal thinning
Fluid within the retina
Fluid beneath the retina
Pigment epithelial detachment
Macular neovascular activity
Geographic-atrophy features
Scar tissue

OCT is central to modern AMD diagnosis and treatment monitoring.

OCT Angiography

OCT angiography, or OCTA, provides non-invasive images of retinal and choroidal blood flow.

It may identify macular neovascularisation without intravenous dye, although it does not replace every role of fluorescein or indocyanine-green angiography.

Fluorescein Angiography

Fluorescein dye is injected into a vein, and photographs are taken as it circulates through the retinal vessels.

The test may demonstrate:

Leakage
Abnormal vascular patterns
Lesion type
Scar tissue
Areas of blocked fluorescence

Indocyanine-Green Angiography

Indocyanine-green angiography visualises deeper choroidal circulation.

It is particularly useful when:

PCV is suspected
There is significant haemorrhage
The diagnosis is uncertain
The response to standard treatment is incomplete

Fundus Autofluorescence

Fundus autofluorescence helps assess the retinal pigment epithelium and may be useful for documenting geographic atrophy and surrounding areas at risk of progression.

The Amsler Grid

What Is an Amsler Grid?

An Amsler grid is a square grid with a central fixation dot.

It is used to detect new central distortion or missing areas.

How to Use It

Wear your usual reading glasses.
Use good lighting.
Hold the grid at your normal reading distance.
Cover one eye.
Look directly at the centre dot.
Keep looking at the dot while checking the surrounding lines.
Repeat with the other eye.

Look for:

Wavy lines
Missing squares
Blurred areas
A new dark spot
A change from your previous test

What Should You Do if It Changes?

Contact your eye clinic promptly if you notice a new change.

Do not wait for the next routine appointment.

What Are Its Limitations?

The Amsler grid is inexpensive and useful but is not perfectly sensitive.

A normal grid does not guarantee that wet AMD is absent, and the test should not replace scheduled examinations or OCT monitoring.

Treatment of Early AMD

Observation

There is no established medical treatment that reverses early AMD.

Management generally focuses on:

Periodic dilated examinations
Smoking cessation
Cardiovascular health
Healthy dietary patterns
Monitoring for progression

Supplements Are Not for Everyone

AREDS2 supplements are not ordinary multivitamins and should not automatically be taken by every older adult.

They are intended for selected patients at a sufficiently high risk of progression.

AREDS2 Supplements

Who May Benefit?

AREDS2 supplementation is generally considered for patients with:

Intermediate AMD in one or both eyes
Late AMD in one eye with appropriate changes in the fellow eye

The formulation can reduce the risk of progression to advanced AMD in suitable high-risk patients. It does not cure AMD or restore lost vision.

What Does a Typical AREDS2 Formulation Contain?

A commonly used AREDS2 formulation includes:

Vitamin C
Vitamin E
Zinc
Copper
Lutein
Zeaxanthin

The exact amounts and zinc formulation may vary among products.

Why Is Beta-Carotene Avoided?

The original AREDS formula contained beta-carotene.

AREDS2 replaced beta-carotene with lutein and zeaxanthin because beta-carotene was associated with an increased lung-cancer risk in former smokers. Long-term AREDS2 follow-up continued to support lutein and zeaxanthin as the preferable carotenoid combination.

Can Fish-Oil Capsules Replace AREDS2?

No.

Adding omega-3 fatty acids to the AREDS formulation did not significantly reduce AMD progression in the primary AREDS2 analysis. Eating fish may form part of a healthy diet, but routine fish-oil supplementation is not an evidence-based substitute for the indicated AREDS2 formula.

Should You Ask Your Doctor First?

Yes.

High-dose supplements may interact with health conditions or medications.

Discuss the formulation with your ophthalmologist and primary-care physician, particularly if you have:

Kidney disease
Bleeding disorders
Significant medication interactions
Difficulty swallowing tablets
A history of smoking
Other nutritional supplements

Treatment of Wet AMD

Anti-VEGF Injections

Intravitreal anti-VEGF therapy is the first-line treatment for most neovascular AMD.

The medication reduces the effect of VEGF and helps control:

Abnormal vessel growth
Leakage
Retinal swelling
Bleeding

Anti-VEGF treatment has transformed the prognosis of wet AMD, allowing many patients to maintain vision and some to gain vision when treatment begins promptly.

What Happens During an Injection?

The clinic generally:

Checks vision and the eye.
Applies anaesthetic drops.
Cleans the eye and eyelids with antiseptic.
Uses a sterile instrument to keep the eyelids open.
Injects medication through the white part of the eye.
Checks the eye after the procedure.

The injection itself is usually brief.

Patients may notice:

Mild irritation
A small red patch on the eye
A moving bubble
Temporary floaters
Mild grittiness

How Many Injections Are Needed?

Wet AMD is usually a chronic condition rather than a one-injection disease.

Treatment may involve:

Initial monthly injections
Fixed intervals
Treatment according to disease activity
A treat-and-extend programme

In treat-and-extend care, the interval may gradually be lengthened when the macula remains inactive and shortened when fluid or haemorrhage returns.

Can Treatment Be Stopped?

Some eyes eventually remain inactive for prolonged periods.

Others reactivate after treatment is reduced or stopped.

Do not miss or discontinue injections without discussing the plan with the retinal specialist.

What if One Drug Does Not Work Well?

The specialist may:

Shorten the interval
Switch anti-VEGF agents
Reconsider the diagnosis
Assess for PCV
Perform additional angiography
Add photodynamic therapy in selected cases

Persistent fluid does not always mean complete treatment failure, but it requires careful interpretation.

What Are the Risks of Intravitreal Injection?

Possible risks include:

Infection inside the eye
Retinal tear or detachment
Raised eye pressure
Inflammation
Bleeding on the eye surface
Lens injury
Rare severe loss of vision

The risk of serious complications from an individual injection is low, but urgent review is required after an injection if there is:

Increasing pain
Increasing redness
Significant light sensitivity
Worsening vision
Thick discharge

Photodynamic Therapy

What Is Photodynamic Therapy?

Photodynamic therapy uses:

An intravenous light-sensitive drug
A low-energy laser applied to the abnormal choroidal vessels

It is used less commonly than anti-VEGF monotherapy for typical wet AMD.

When Might It Be Used?

It may be considered for:

Polypoidal choroidal vasculopathy
Selected persistent lesions
Certain abnormal vascular patterns
Cases with incomplete response to injections

Laser Treatment

Thermal laser is rarely used for ordinary central wet AMD because it may damage the overlying retina and create a permanent blind spot.

It may still have a limited role in selected lesions located away from the centre of the macula.

What Happens if Wet AMD Is Not Treated?

Untreated wet AMD may lead to:

Continued leakage
Retinal bleeding
Photoreceptor damage
Macular fibrosis
Disciform scarring
Permanent central visual loss

Treatment is most effective before extensive permanent structural damage has occurred.

Lifestyle and Risk Reduction

Stop Smoking

Smoking cessation is the most important modifiable preventive action.

Stopping smoking also benefits:

Cardiovascular health
Lung health
Surgical outcomes
General longevity

Control Blood Pressure and Vascular Risk

Work with your physician to manage:

Hypertension
Diabetes
High cholesterol
Cardiovascular disease
Obesity

This does not guarantee that AMD will stabilise, but it supports overall ocular and systemic health.

Eat a Balanced Diet

A practical dietary approach includes:

Dark leafy vegetables
Colourful vegetables
Fruit
Fish
Nuts
Whole grains
Healthy unsaturated fats

Avoid relying on one “superfood” or unproven supplement.

Exercise Regularly

Exercise can support:

Blood-pressure control
Weight management
Cardiovascular health
Mobility
General well-being

Choose activity appropriate for your medical condition.

Protect the Eyes

Wear appropriate sunglasses outdoors for comfort and general ultraviolet protection.

Sunglasses do not replace medical monitoring or proven treatment.

Can AMD Be Prevented?

AMD cannot always be prevented because age and genetics cannot be changed.

Risk may be reduced or progression slowed through:

Not smoking
Managing cardiovascular disease
Maintaining a healthy lifestyle
Attending routine eye examinations
Taking AREDS2 supplements when specifically indicated
Seeking urgent assessment for new distortion or central blur
Adhering to anti-VEGF treatment when wet AMD develops

Does AMD Cause Complete Blindness?

AMD generally damages central rather than peripheral vision.

It does not usually cause complete absence of light perception.

However, advanced bilateral AMD may prevent:

Reading ordinary print
Recognising faces
Driving
Working at visually demanding tasks
Performing activities without assistance

Patients may meet legal definitions of blindness despite retaining useful peripheral vision.

Can You Still Drive With AMD?

Driving ability depends on:

Visual acuity
Visual fields
Contrast sensitivity
Glare
Vision in both eyes
Local licensing requirements
The stage and location of AMD

A patient may meet a basic eye-chart standard but still struggle with:

Night driving
Rain
Pedestrian detection
Road-sign recognition
Low-contrast hazards

Stop driving and arrange assessment if you no longer feel safe.

Reading With AMD

Helpful strategies include:

Brighter directed lighting
Larger print
Electronic magnification
High-contrast settings
Tablet or phone enlargement
Text-to-speech software
Audiobooks
Reading stands
Eccentric-viewing training

A low-vision specialist can recommend devices based on the location and severity of the central visual loss.

Visual Rehabilitation

What Is Low-Vision Rehabilitation?

Low-vision rehabilitation helps patients use their remaining vision effectively.

It may include:

Magnifiers
Telescopic devices
Electronic readers
Screen enlargement
Contrast enhancement
Lighting advice
Mobility training
Occupational therapy
Home-safety modification

Emotional Support

Central visual loss can affect:

Confidence
Independence
Mood
Social participation
Risk of falls

Patients experiencing anxiety or low mood should seek support rather than treating emotional distress as an unavoidable part of AMD.

Cataract Surgery and AMD

Can a Patient With AMD Have Cataract Surgery?

Yes.

Cataract surgery may improve vision when a cataract contributes significantly to blur, glare or reduced contrast.

The degree of improvement depends on the health of the macula.

AREDS data found visual-acuity improvement after cataract surgery across different AMD severities, although the average gain was smaller in more advanced disease.

Does Cataract Surgery Cure AMD?

No.

Cataract surgery clears the cloudy lens but does not treat:

Drusen
Geographic atrophy
Macular neovascularisation
Macular scarring

Does Cataract Surgery Worsen AMD?

Evidence has been mixed across observational studies.

Large AREDS analyses found no clear increased risk of progression to advanced AMD after cataract surgery, while some long-term observational meta-analyses have reported associations. Current clinical decision-making generally weighs the expected cataract-related visual benefit against the individual macular prognosis rather than withholding surgery solely because AMD is present. Ongoing retinal follow-up remains important.

Which Lens Is Suitable?

A monofocal or toric monofocal lens is commonly favoured when AMD is visually significant because it concentrates light into one principal focus.

Multifocal and trifocal lenses require caution because they divide light between focal points and may reduce contrast in an eye whose macular function is already compromised.

AMD and the Other Eye

If one eye develops late AMD, the fellow eye may have an increased risk of progression.

Monitoring may include:

More frequent examination
OCT
Home Amsler-grid testing
AREDS2 supplementation when indicated
Immediate reporting of new symptoms

Do not rely entirely on the better eye to identify change.

Common Myths

“AMD Means I Will Become Completely Blind”

AMD primarily affects central vision.

Peripheral vision is usually retained, although severe bilateral disease can still cause major disability.

“All Dry AMD Becomes Wet”

No.

Dry AMD may remain stable, progress to geographic atrophy, convert to wet AMD or follow a mixed course.

“Eye Vitamins Cure AMD”

No.

AREDS2 supplements reduce progression risk in selected patients. They do not remove drusen, reverse atrophy or replace anti-VEGF injections.

“If My Vision Is Good, My Macula Must Be Normal”

Not necessarily.

Early and intermediate AMD can be present despite good high-contrast visual acuity.

“One Injection Cures Wet AMD”

Wet AMD usually requires ongoing monitoring and repeated treatment.

“There Is No Point Treating an Older Patient”

Age alone does not determine whether treatment is worthwhile.

Visual potential, overall health, treatment burden and the patient’s goals should guide decisions.

Frequently Asked Questions

Is Macular Degeneration the Same as AMD?

AMD refers specifically to age-related macular degeneration.

Other conditions can also damage the macula, including:

Diabetic macular oedema
Epiretinal membrane
Macular hole
High-myopia-related degeneration
Retinal-vein occlusion
Inflammatory disease

At What Age Does AMD Begin?

AMD most commonly affects people over 55, but age-related changes can be detected earlier.

Symptoms in a younger patient should not automatically be labelled AMD without a proper examination.

Is AMD Hereditary?

Genetics plays an important role, but AMD is not inherited through one simple gene.

Having an affected close relative increases risk but does not guarantee that you will develop advanced disease.

Should My Children Be Screened?

Adult children of patients with AMD should:

Avoid smoking
Maintain general vascular health
Attend routine comprehensive eye examinations as they age
Seek review for central visual symptoms

Can Glasses Correct AMD?

Glasses may improve coexisting short-sightedness, long-sightedness or astigmatism.

They cannot restore retinal cells damaged by advanced AMD.

Is Wet AMD Worse Than Dry AMD?

Wet AMD often causes more rapid visual loss.

Geographic atrophy can also cause severe and irreversible central visual impairment, usually over a longer period.

Can Dry AMD Turn Into Wet AMD?

Yes.

New distortion, central blur or a dark spot may indicate conversion and requires prompt examination.

Can Wet AMD Become Dry?

An eye treated for wet AMD may become inactive but still have:

Drusen
Atrophy
Scar tissue
Underlying dry AMD features

The eye remains at risk of reactivation.

Do Anti-VEGF Injections Improve Vision?

They may:

Improve vision
Stabilise vision
Prevent further deterioration

The result depends on how early treatment begins and how much permanent damage is already present.

Are Eye Injections Painful?

The eye is numbed before treatment.

Patients commonly feel:

Pressure
Brief discomfort
Mild grittiness afterwards

Severe increasing pain is not normal and requires urgent assessment.

Can I Take AREDS2 if I Do Not Have AMD?

It is not routinely recommended solely to prevent AMD in a person without the indicated retinal findings.

Can Supplements Replace a Healthy Diet?

No.

Supplements are intended for specific disease stages and should complement rather than replace a balanced diet.

Should Former Smokers Avoid Beta-Carotene?

Yes.

Use an AREDS2 formulation containing lutein and zeaxanthin rather than beta-carotene unless specifically advised otherwise.

How Often Should AMD Be Checked?

The interval depends on:

Disease stage
Symptoms
OCT findings
Condition of the other eye
Previous wet AMD
Treatment schedule
Other retinal disease

Follow the interval recommended by your ophthalmologist.

When to Seek Urgent Review

Arrange urgent ophthalmic assessment for:

New wavy or bent lines
A sudden central blur
A new central dark spot
Sudden loss of reading ability
Objects appearing smaller in one eye
Sudden deterioration on an Amsler grid
New retinal bleeding noted by another doctor

Seek immediate assessment for severe vision loss or symptoms associated with:

New flashes
A sudden shower of floaters
A curtain or shadow
Eye pain
Marked redness

Flashes, floaters and a curtain are not typical AMD symptoms and may indicate a retinal tear or detachment.

An AMD Monitoring Checklist

At Home

Test each eye separately.
Use an Amsler grid if advised.
Note new distortion or missing areas.
Use adequate lighting.
Do not ignore sudden central changes.
Continue prescribed supplements or injections.
Stop smoking.

At Follow-Up

Your ophthalmologist may assess:

Visual acuity
Symptoms
Drusen and pigment changes
OCT fluid
Geographic-atrophy progression
Haemorrhage
Treatment interval
The fellow eye

Bring to Your Appointment

Current medication list
Supplement packaging
A record of symptoms
Amsler-grid changes
Previous retinal reports when available
Details of previous injections

The Bottom Line

Age-related macular degeneration is a progressive condition affecting the macula and central vision.

The main forms are:

Early and intermediate dry AMD: Drusen and pigmentary changes with variable progression risk
Geographic atrophy: Progressive loss of retinal pigment epithelium and photoreceptors
Wet AMD: Abnormal leaking or bleeding blood vessels beneath or within the retina

The most important symptoms are:

Central blur
Wavy or distorted lines
A dark or missing central spot
Difficulty reading
Reduced contrast
Difficulty recognising faces

The most important modifiable risk factor is smoking.

Treatment depends on the stage:

Early AMD is generally monitored.
AREDS2 supplements may reduce progression in suitable patients with intermediate or advanced disease.
Complement-inhibitor injections may slow geographic-atrophy enlargement in selected patients where available.
Anti-VEGF injections are the main treatment for wet AMD.
Photodynamic therapy may be useful in selected cases, particularly PCV.
Low-vision rehabilitation can preserve independence when permanent visual loss has occurred.

New distortion, central blur or a dark spot should be assessed urgently because early treatment of wet AMD offers the best chance of preserving useful central vision.

References

Fleckenstein M, Keenan TDL, Guymer RH, Chakravarthy U, Schmitz-Valckenberg S, Klaver CCW, Wong WT, Chew EY. Age-related macular degeneration: a review. JAMA. 2024;331(2):147–157. doi:10.1001/jama.2023.26074. PMID: 38193957.
Wong WL, Su X, Li X, Cheung CMG, Klein R, Cheng CY, Wong TY. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health. 2014;2(2)–e116. doi:10.1016/S2214-109X(13)70145-1. PMID: 25104651.
Age-Related Eye Disease Study 2 Research Group. Lutein plus zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the AREDS2 randomised clinical trial. JAMA. 2013;309(19):2005–2015. doi:10.1001/jama.2013.4997. PMID: 23644932.
Chew EY, Clemons TE, Agrón E, et al. Long-term outcomes of adding lutein/zeaxanthin and omega-3 fatty acids to the AREDS supplements on age-related macular degeneration progression: AREDS2 Report 28. JAMA Ophthalmol. 2022;140(7):692–698. doi:10.1001/jamaophthalmol.2022.1640. PMID: 35653117.
Cong R, Zhou B, Sun Q, Gu H, Tang N, Wang B. Smoking and the risk of age-related macular degeneration: a meta-analysis. Ann Epidemiol. 2008;18(8):647–656. PMID: 18652983.
Nguyen J, et al. Genetics and age-related macular degeneration. Curr Opin Ophthalmol. 2024. PMID: 38538345.
Heier JS, Lad EM, Holz FG, et al. Pegcetacoplan for geographic atrophy secondary to age-related macular degeneration: the OAKS and DERBY phase 3 trials. Lancet. 2023;402(10411):1434–1448. doi:10.1016/S0140-6736(23)01520-9. PMID: 37865470.
Khanani AM, Patel SS, Staurenghi G, et al. Efficacy and safety of avacincaptad pegol in geographic atrophy: 12-month results from the GATHER2 phase 3 trial. Lancet. 2023. PMID: 37696275.
Cheng S, et al. Treatment of neovascular age-related macular degeneration: current therapies and future directions. Int J Mol Sci. 2024. PMID: 39099595.
Cheung CMG, Lai TYY, Ruamviboonsuk P, et al. Polypoidal choroidal vasculopathy: definition, pathogenesis, diagnosis and management. Ophthalmology. 2018. PMID: 29331556.
Cheung CMG, Lai TYY, Teo K, et al. Polypoidal choroidal vasculopathy: consensus nomenclature and diagnostic criteria. Ophthalmology. 2021. PMID: 32795496.
Bjerager J, et al. Diagnostic accuracy of the Amsler grid test for detecting neovascular age-related macular degeneration: a systematic review and meta-analysis. JAMA Ophthalmol. 2023. PMID: 36795396.
Forooghian F, Agrón E, Clemons TE, et al. Risk of advanced age-related macular degeneration after cataract surgery in the Age-Related Eye Disease Study: AREDS Report 25. Ophthalmology. 2009. PMID: 19091420.
Forooghian F, Agrón E, Clemons TE, et al. Visual-acuity outcomes after cataract surgery in patients with age-related macular degeneration: AREDS Report 27. Ophthalmology. 2009. PMID: 19700198.
National Eye Institute. Age-related macular degeneration. National Institutes of Health.